245 related articles for article (PubMed ID: 1346095)
1. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.
Wun TC
Blood; 1992 Jan; 79(2):430-8. PubMed ID: 1346095
[TBL] [Abstract][Full Text] [Related]
2. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
Welsch DJ; Novotny WF; Wun TC
Thromb Res; 1991 Oct; 64(2):213-22. PubMed ID: 1811340
[TBL] [Abstract][Full Text] [Related]
3. Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitors from Hep G2 hepatoma, Chang liver, and SK hepatoma cells. A comparative study.
Wun TC; Huang MD; Kretzmer KK; Palmier MO; Day KC; Bulock JW; Fok KF; Broze GJ
J Biol Chem; 1990 Sep; 265(27):16096-101. PubMed ID: 2168880
[TBL] [Abstract][Full Text] [Related]
4. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.
Broze GJ; Warren LA; Novotny WF; Higuchi DA; Girard JJ; Miletich JP
Blood; 1988 Feb; 71(2):335-43. PubMed ID: 3422166
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
[TBL] [Abstract][Full Text] [Related]
6. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI.
Lindahl AK; Abildgaard U; Larsen ML; Staalesen R; Hammer AK; Sandset PM; Nordfang O; Beck TC
Thromb Res; 1991 Jun; 62(6):607-14. PubMed ID: 1926055
[TBL] [Abstract][Full Text] [Related]
7. The lipoprotein-associated coagulation inhibitor.
Broze GJ; Girard TJ; Novotny WF
Prog Hemost Thromb; 1991; 10():243-68. PubMed ID: 2008533
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein.
Girard TJ; MacPhail LA; Likert KM; Novotny WF; Miletich JP; Broze GJ
Science; 1990 Jun; 248(4961):1421-4. PubMed ID: 1972598
[TBL] [Abstract][Full Text] [Related]
9. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation.
Lindahl AK; Abildgaard U; Larsen ML; Aamodt LM; Nordfang O; Beck TC
Thromb Res Suppl; 1991; 14():39-48. PubMed ID: 1658969
[TBL] [Abstract][Full Text] [Related]
10. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides.
Sie P; Ofosu F; Fernandez F; Buchanan MR; Petitou M; Boneu B
Br J Haematol; 1986 Dec; 64(4):707-14. PubMed ID: 2432917
[TBL] [Abstract][Full Text] [Related]
11. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor.
Lindahl AK; Abildgaard U; Staalesen R
Thromb Res; 1991 Oct; 64(2):155-68. PubMed ID: 1811336
[TBL] [Abstract][Full Text] [Related]
12. Utilization of a continuous flow reactor to study the lipoprotein-associated coagulation inhibitor (LACI) that inhibits tissue factor.
Gemmell CH; Broze GJ; Turitto VT; Nemerson Y
Blood; 1990 Dec; 76(11):2266-71. PubMed ID: 2257300
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma.
Gerotziafas GT; Bara L; Bloch MF; Makris PE; Samama MM
Blood Coagul Fibrinolysis; 1998 Oct; 9(7):571-80. PubMed ID: 9863704
[TBL] [Abstract][Full Text] [Related]
15. Coagulation Testing in the Core Laboratory.
Winter WE; Flax SD; Harris NS
Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions.
Pedersen AH; Nordfang O; Norris F; Wiberg FC; Christensen PM; Moeller KB; Meidahl-Pedersen J; Beck TC; Norris K; Hedner U
J Biol Chem; 1990 Oct; 265(28):16786-93. PubMed ID: 2211593
[TBL] [Abstract][Full Text] [Related]
17. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
Fernández JA; Petäjä J; Griffin JH
Thromb Haemost; 1999 Nov; 82(5):1462-8. PubMed ID: 10595639
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.
Novotny WF; Girard TJ; Miletich JP; Broze GJ
J Biol Chem; 1989 Nov; 264(31):18832-7. PubMed ID: 2553722
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays.
Valentin S; Ostergaard P; Kristensen H; Nordfang O
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):629-35. PubMed ID: 1664252
[TBL] [Abstract][Full Text] [Related]
20. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor.
Novotny WF; Palmier M; Wun TC; Broze GJ; Miletich JP
Blood; 1991 Jul; 78(2):394-400. PubMed ID: 2070077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
